Two different kinds of salvage chemotherapy regimens produced similar outcomes in a study involving 41 individuals with relapsed/refractory acute myeloid leukemia (rrAML). However, 1 treatment was substantially less expensive. Participants with rrAML were treated with either clofarabine- (GCLAC; n=22) or cladribine- (CLAG; n=19) based therapy. Investigators looked at complete response rate, percentage of patients who underwent allogenic stem cell transplant (allo-SCT), relapse free survival, and overall survival. The small trial did not produce statistically significant differences in:
- Complete remission with or without hematologic recovery: 64% for GCLAC, 47% for CLAG.
- Percentage of patient who underwent allo-SCT: 45% and 25%, respectively.
- Relapse-free survival: 1.59 vs 1.03 years, respectively.
- Overall survival: 1.03 vs 0.70 years, respectively.
The average wholesale price was nearly $61,000/patient/cycle for GCLAC, vs nearly $5,000 for CLAG.
Muluneh B, Buhlinger K, Deal A, et al. A Comparison of clofarabine-based (GCLAC) and cladribine-based (CLAG) salvage chemotherapy for relapsed/refractory AML. [Published online ahead of print September 22, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.09.016.
This Week's Must Reads
Cochrane on Use of TPO-RAs to Prevent, Treat CIT, Cochrane; 2017 Nov 27; Zhang, Chuai, Nie, et al
Guideline on Preventing VTE in Pediatric Cancer, J Thromb Haemost; ePub 2017 Nov 27; Tullius, et al
Conditioning Regimens After HCT Compared in ALL, Biol Blood Marrow Transplant; ePub 2017 Nov 29; Kebriaei, et al
Acute Kidney Injury in Young Allo-HCT Recipients, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Koh, et al
Moral Distress in HCT Professionals Evaluated, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Neumann, et al
Must Reads in AML
Two Salvage Chemotherapy Regimens Evaluated in AML, Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 22; Muluneh, et al
Cochrane on Optimizing Chemo, Radiotherapy for HL, Cochrane; 2017 Sep 4; Franklin, Eichenauer, et al
FDA Approves Mylotarg for Certain Form of AML, Wyeth news release; 2017 Sep 1
Impact of Fluid Overload on HSCT Outcomes, Biol Blood Marrow Transplant; ePub 2017 Aug 24; Rondón, et al
Health Care Use in People with AML at End of Life, J Clin Oncol; ePub 2017 Aug 7; Wang, Zeidan, et al